INTRODUCTION TO MSC AND TREG
============================

Since the discovery of mesenchymal stem cells (MSC) in bone marrow by [@B35], researchers were able to isolate these adherent cells from various postnatal and adult tissue sources ([@B74]; [@B103]; [@B49]; [@B3]). MSC are self-renewing and capable of forming colonies while retaining their multilineage differentiation potential. They are able to differentiate into adipocytes, chondrocytes, osteoblasts, and myocytes ([@B74]; [@B22]). These features represent part of the criteria that define MSC ([@B27]). MSC are immunophenotypically characterized by the expression of the cell surface markers CD73, CD90, CD105, and HLA-DR^low^, and the absence of CD11b, CD14, CD19, CD34, CD45, and CD79α. Interest in MSC for their use in transplantation was fostered when it was first discovered that MSC possess T cell suppressive properties ([@B9]). Intensive research was undertaken to unravel the mechanisms by which MSC exert their immunomodulatory functions. Besides CD4^+^ helper T cells and CD8^+^ cytotoxic T cells, activated B cells and natural killer (NK) cells are also susceptible to the suppressive activity of MSC ([@B20]; [@B91]). Further, MSC hamper the maturation of dendritic cells (DC) through the downregulation of MHC class II molecules and co-stimulatory molecules ([@B1]; [@B54]; [@B71]). In addition to these immunosuppressive effects, MSC also have immunosupportive properties; they delay the apoptosis of neutrophils, preserving them to be readily available to counter infections ([@B77]). Immunomodulation by MSC is mediated by cell--cell contact and the release of soluble factors. Important mediators are indoleamine 2,3-dioxygenase (IDO), transforming growth factor-beta (TGF-β), interleukin-10 (IL-10), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), human leukocyte antigen-G5 (HLA-G5), and nitric oxide (NO; [@B26]; [@B67]; [@B43]; [@B11]; [@B70]; [@B84]; [@B51]; [@B23]). The ability of MSC to exert their immunosuppressive function requires MSC activation in a pro-inflammatory microenvironment through the presence of cytokines like interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-1α, and IL-1β ([@B21]). Collecting *in vivo* data suggest that MSC could be used as immunotherapy ([@B9]; [@B75]). In clinical studies MSC have successfully attenuated graft-versus-host-disease (GvHD) after hematopoietic stem cell transplantation ([@B61], [@B60]). Currently, research groups strive to confirm the safety and feasibility of MSC therapy in solid organ transplantation ([@B52]; [@B73]).

Primarily T cells are targeted by the immunosuppressive effect of MSC which raises the question, to what extent MSC affect T cells with immunomodulatory properties. Regulatory T cells (Treg) were first characterized by [@B82] as activated CD4^+^ T cells expressing CD25, the IL-2 receptor alpha-chain, which are involved in the maintenance of tolerance to self-antigens. Human Treg are commonly characterized by their expression of the transcription factor forkhead box P3 (FOXP3) and the FOXP3 reciprocal expression of CD127, the IL-7 receptor alpha-chain ([@B33]; [@B62]; [@B86]); additional markers are the co-stimulatory molecules cytotoxic T lymphocyte antigen-4 (CTLA-4) and the glucocorticoid-induced TNF receptor-related protein (GITR; [@B78]; [@B83]; [@B93]; [@B65]; [@B89]). While a unique marker for human Treg is yet to be identified, FOXP3 presents a reliable marker for Treg in mice ([@B101]).

The importance of Treg in the maintenance of tolerance is highlighted in humans suffering from immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX; [@B12]; [@B58]). IPEX patients lack functional Treg as a result of a point mutation in the *Foxp3* gene ([@B5]). In other autoimmune diseases, the role of Treg remains controversial ([@B15]). The immunomodulating nature of Treg made them interesting candidates for the induction of transplantation tolerance. Indeed, Treg have been reported to control alloreactivity by inhibiting the functionality of cell types similar to those suppressed by MSC; Treg hamper the proliferation of CD4^+^ T cells, CD8^+^ T cells, and DC ([@B98]; [@B13]; [@B94]; [@B46]). Further, molecules associated with the tolerogenic and suppressive function of Treg partially overlap with those involved in MSC-mediated immunomodulation and include IL-10, TGF-β, and heme oxygenase-1 (HO-1; [@B94]). In addition, it has been hypothesized that Treg are able to influence their target cells in a granzyme B-dependent and perforin-dependent manner ([@B44]; [@B40]). Results from different humanized mouse models and clinical studies in patients with GvHD encourage the use of freshly isolated or *ex vivo* expanded Treg ([@B97]; [@B53]; [@B69]; [@B14]; [@B25]). Despite the indication that Treg therapy is promising and well tolerated in patients receiving stem cell treatment, clinical information about the application of Treg in solid organ transplantation is still lacking. However, Treg represent one of the immunomodulatory cell types whose clinical safety is currently under investigation ([@B66]; [@B85]).

Both MSC and Treg are able to influence the adaptive immune system by utilizing similar and distinct mechanisms. Therefore, it is of interest whether the overlapping mechanisms cause interference of the immunomodulatory properties of both cell types.

*IN VITRO* INTERACTION BETWEEN MSC AND TREG
===========================================

Recently we investigated the interaction between MSC and Treg in a transplantation setting ([@B29]). We found that MSC derived from healthy kidney donors permitted the function of Treg from healthy donors as well as Treg from renal transplant patients. Vice versa, Treg did not hamper MSC function.

One of the first indications that T cells with a regulatory phenotype are unaffected by the suppressive capacities of MSC was provided by [@B64]. This group reported that although autologous MSC and third-party MSC were able to suppress the proliferation of CD4^+^ T cells and CD8^+^ T cells in primary mixed lymphocyte cultures (MLC), after re-stimulation in secondary MLC the numbers of CD4^+^ T cells co-expressing CD25 and/or CTLA-4 increased. This indicates an MSC-dependent preferential differentiation into T cells with a regulatory phenotype. Similar observations were made by [@B76] after PBMC--MSC co-culture. In addition, IL-2 stimulation of PBMC in the presence of MSC also led to elevated proportions of CD4^+^CD25^+^ cells ([@B1]). It has to be considered that due to lack of appropriate markers no distinction could be made between activated effector cells and Treg in these early research studies. Employing newly discovered markers, [@B24] performed an extensive study to shed light on the T cell population that is most responsive to the MSC-stimulus for Treg generation. The largest numbers of CD4^+^CD25^+^FOXP3^+^CD127^-^ Treg were found when MSC were cultured with immunoselected CD3^+^CD45RA^+^ or CD3^+^CD45RO^+^ fractions. Co-culture of MSC with different Treg populations such as CD4^+^CD25^+^ cells, CD4^+^CD25^+^CD45RA^+^ cells, and CD4^+^CD25^+^CD45RO^+^ cells maintained FOXP3 expression, CD127 downregulation, and the immunosuppressive activities of Treg for about 2 weeks. In the absence of MSC the Treg populations lost their suppressive capacities during this period.

The apparent interplay between MSC and Treg in the allosuppression of T cell proliferation triggered researchers' interest in the factors and mediators involved. Although conflicting data exist, it is the current opinion that key factors involved in Treg induction by MSC are MSC-derived TGF-β and PGE2 ([@B76]; [@B31]). TGF-β is a key regulator of the initiation and maintenance of FOXP3 expression, and the suppressive function of Treg ([@B19]; [@B36]). PGE2 is an immunosuppressant that inhibits T cell mitogenesis and the production of IL-2. TGF-β and PGE2 are constitutively produced by MSC. Secretion of these two immunomodulatory molecules can be increased through "MSC licensing," the activation of MSC with TNF-α and IFN-γ which improves their immunosuppressive capacity ([@B30]; [@B81]). MSC-derived PGE2 also exerts suppressive functions by increasing the IL-10 production of macrophages and by limiting monocyte differentiation into DC ([@B72]; [@B92]). It has also been reported that PGE2 induces a regulatory phenotype in CD4^+^CD25^-^ T cells by modulating the expression of FOXP3 and therefore contributes to Treg function ([@B6]). In addition, cell--cell contact seems to play a non-redundant role in the induction of Treg ([@B31]). After culture of CD4^+^ cells with MSC, increases in mRNA levels of CD25 and FOXP3 mRNA were only detected when cells were in close proximity; when cells were separated by a tissue culture insert, this effect was not observed. For enhancement of FOXP3 expression in PBMC, however, direct MSC--PBMC contact was not required. This suggests that cell--cell contact between certain PBMC subpopulations contributes to the FOXP3 expression and substitutes for MSC--CD4^+^ cell contact interactions. Another factor influencing the immunomodulatory effect of MSC on alloactivated T cells as well as the expansion of CD4^+^CD25^+^FOXP3^+^ Treg is the soluble protein HLA-G5 ([@B87]). In the presence of anti-HLA-G5 antibody, MSC-mediated immunosuppression was hampered. Neutralization of the HLA-G5 protein led to a decrease in the generation of CD4^+^CD25^+^FOXP3^+^ T cells. In addition, the tryptophan-catabolizing enzyme IDO was identified as a crucial modulator of the immunosuppressive effect of MSC ([@B67]; [@B55]). Using a renal allograft model, [@B37] investigated whether MSC-driven T cell suppression is also a consequence of the induction of Treg. Graft survival in untreated kidney recipients was significantly lower than graft survival in mice after MSC treatment. Increased serum levels of kynurenine in MSC-treated allograft recipients indicated increased IDO enzymatic activity and correlated with higher frequencies of CD4^+^CD25^+^FOXP3^+^ Treg in recipient spleen and in the allograft. In this model recipient treatment with IDO-knockout MSC or the IDO inhibitor 1-methyl-tryptophan did not achieve graft tolerance. Therefore, the expression of functional IDO seems to be a prerequisite for MSC-mediated graft acceptance via direct T cell suppression as well as indirect modulation of the graft recipient's immune system through Treg induction. Skewing of CD4^+^ T cell differentiation toward a more regulatory phenotype leads to the inhibition of T helper 17 (Th17) cell differentiation, an effect which is partly caused by MSC-derived IDO and PGE2 ([@B39]; [@B95]). The role of IL-17, produced by Th17 cells, in the onset of GvHD is still controversial. Disease-ameliorating effects and an inductive role of *ex vivo* differentiated Th17 cells have been reported ([@B17]; [@B56]).

In summary, the mechanisms employed by MSC to inhibit effector T cell proliferation overlap with the mechanisms involved in Treg induction, yet, they do not interfere with Treg function.

*IN VIVO* INTERACTION BETWEEN MSC AND TREG
==========================================

Whether MSC-mediated *in vitro* induction of Treg can be translated into the *in vivo* setting or even into the clinical setting remains to be thoroughly investigated. To date little evidence from animal models exists. One of the first *in vivo* studies, reporting the induction of Treg after MSC administration, was conducted by [@B41]. Mice suffering from induced colitis were treated with a systemic infusion of human MSC. MSC ameliorated the severity of colitis through the reduction of inflammatory cytokines and chemokines and an increase of IL-10 concentrations; an overall downregulation of Th1-driven autoimmune responses and inflammatory responses was observed. Although MSC infusion impaired the expansion of Th1 cells, functional CD4^+^CD25^+^FOXP3^+^ Treg were induced, confirming the *in vitro* MSC--Treg interplay.

A similar observation was recently made in a mouse model of allergen-driven airway inflammation ([@B57]). Systemic administration of allogeneic mouse MSC reduced the classical pathologies in this model as airway-mucus secretion, allergen-driven lung eosinophilia, and IgE induction were diminished. The improved pathological outcome coincided with a higher percentage of CD4^+^FOXP3^+^ cells in both lungs and spleens of MSC-treated mice when compared to control mice. [@B57] demonstrated the importance of Treg induction by MSC in this model; after *in vivo* depletion of Treg with cyclophosphamide an amelioration of the disease pathologies was observed, which serves as further evidence that the capability of MSC therapy to induce Treg is essential for this therapeutic modality.

In transplantation, one of the first models demonstrating the *in vivo* induction of Treg after MSC administration was described by [@B18]. In a semi-allogeneic heart transplant mouse model, pre-transplant infusion of donor-derived MSC into the portal vein led to T cell hyporesponsiveness, prolonged cardiac allograft survival and expanded donor-specific Treg expressing CD4, CD25, and FOXP3. Similar observations were made after administration of recipient-derived MSC. Of relevance for the translation into a clinical setting, this group noticed that double pre-transplant infusions were more tolerogenically effective than a single MSC infusion. In contrast, post-transplant infusion of MSC was not effective. This suggests that pre-exposure to donor-MSC is required or that pre-activation of MSC might be necessary for MSC to successfully exert their tolerogenic action when graft alloantigens challenge the recipient's immune system.

Further evidence that the generation of Treg by MSC contributes to graft survival is provided by a kidney allograft mouse model ([@B37]). In contrast to the findings by [@B18], in this model intravenous administration of MSC 24 h after renal transplantation inhibited T cell proliferation. In tolerant recipients a Th2-dominant cytokine shift was observed as a significant decrease of IFN-γ production was detected while IL-4 levels were significantly increased. Further, in recipient spleens, frequencies of CD4^+^CD25^+^FOXP3^+^ T cells were higher in MSC-treated mice. [@B37] also found a significant increase of intragraft FOXP3^+^ cells after MSC treatment suggesting Treg recruitment to the renal allograft. In this model, depletion of Treg using an anti-CD25 monoclonal antibody also reversed the beneficial effect of MSC therapy. CD25^+^ T cell depletion caused graft rejection despite MSC treatment. This study again emphasized the importance of IDO as a mediator of MSC function. MSC derived from IDO-knockout mice were not able to induce graft tolerance. In a similar fashion, *in vivo* inhibition of IDO also abrogated the tolerogenic effect of MSC revealing a significant role of IDO in MSC immunosuppressivity.

INTERACTION BETWEEN MSC AND TREG IN THE CLINICAL SETTING
========================================================

Results from preclinical studies support the plethora of *in vitro* data and confirm that MSC-mediated induction of Treg has functional relevance *in vivo*. Nevertheless, to date only one clinical study looked into this aspect of MSC therapy in a transplantation setting ([@B73]). In this safety and clinical feasibility study, autologous MSC were administered intravenously to two patients 7 days after they received living-related kidney grafts. Despite a concerning increase in serum-creatine levels after MSC infusion, stable graft function was reported for both patients 1 year after transplantation. Both patients received induction therapy in combination with standard maintenance immunosuppression. The induction regimen consisting of basiliximab and low-dose rabbit anti-thymocyte globulin (rATG) caused a profound depletion of CD4^+^ and CD8^+^ T cells in the peripheral blood in MSC-treated and non-MSC treated patients during the first 30 days. In patients with MSC therapy the number of CD4^+^ T cells remained lower during the entire follow-up time when compared to the number of CD4^+^ T cells in non-MSC patients. In contrast, CD8^+^ T cell repopulation to pre-transplant levels was achieved in both patient groups. During T cell depletion, the percentage of CD4^+^CD25^+^FOXP3^+^CD127^-^ Treg within the total CD4^+^ T cell population was reduced. However, after 30 days the percentage of Treg increased in both MSC-treated patients. The memory CD8^+^CD45RO^+^RA^-^ T cells in both MSC-treated patients remained lower than pre-transplant levels after 30 days post-transplant despite the full recovery of total CD8^+^ T cell counts around this time-point. This effect was less prominent in patients who did not receive MSC. These findings indicate that in comparison to the immunosuppressive medication MSC might have an additional inhibitory effect on memory CD8^+^ T cell proliferation. The combination of reduced memory CD8^+^ T cells and increased percentages of Treg suggests that MSC treatment leads to a more pro-tolerogenic environment. Yet, it cannot entirely be ruled out that the observed effects are due to the MSC treatment and not evoked by the rATG induction therapy. More clinical experience with MSC therapy is required to obtain confident data.

INTERACTION OF MSC AND TREG WITH IMMUNOSUPPRESSIVE MEDICATION
=============================================================

Achieving graft tolerance, the long-term goal in transplantation immunology, is a major challenge. Controlling the immune response to donor-antigen in the graft recipient is currently accomplished by the administration of immunosuppressive drugs. Upon the introduction of novel cellular immunotherapies they will be applied in combination with standard immunosuppressive regimens. It therefore has to be considered that these drugs may not be permissive for MSC and/or Treg function. Conversely, MSC and Treg may interfere with the efficacy of the agents.

*In vitro* studies show that MSC reduce the efficacy of rapamycin and tacrolimus and, conversely, that these immunomodulatory agents negatively affect MSC function ([@B48]; [@B16]). However, cumulative inhibition of effector cell proliferation has been reported for combination therapy of MSC with mycophenolic acid (MPA) while dexamethasone did not influence MSC functionality. A synergistic effect of MSC and mycophenolate mofetil (MMF), the prodrug of MPA, on prolonged graft survival was observed in a fully allogeneic heart transplant mouse model ([@B28]); treatment with MSC and cyclosporine A failed to prolong allograft survival. In contrast to *in vitro* results, combination therapy of MSC and rapamycin achieved long-term heart allograft tolerance in mice and increased the frequency of splenic CD4^+^CD25^+^FOXP3^+^ T cells ([@B38]). This finding is important as rapamycin is currently used for the *ex vivo* expansion of Treg ([@B10]). In renal transplant patients rapamycin led to an increase of CD4^+^CD25^+^FOXP3^+^ Treg ([@B47]). A recent study by [@B63] indicated that *in vitro* rapamycin had better synergistic effects on Treg function than cyclosporine A and tacrolimus. Subsequent adoptive infusion of donor-alloantigen-specific Treg in combination with low-dose of rapamycin delayed the acute rejection of kidney allografts in *Cynomolgus* monkeys. In addition, selective expansion of donor-type CD4^+^CD25^+^FOXP3^+^ Treg after *in vivo* administration of rapamycin in combination with IL-2 suppressed acute GvHD in mice ([@B90]).

The interactions between both immunomodulatory cell types and immunosuppressive drugs demonstrate that the choice of immunosuppressive regimen will affect the outcome of cellular therapies.

HETEROGENEITY OF THE TREG POPULATION
====================================

Recent developments in Treg research revealed a heterogeneity of the Treg population. Apart from the well-described thymic-derived naturally occurring CD4^+^CD25^+^CD127-FOXP3^+^ Treg (nTreg), other Treg subsets have been identified. Of these the most studied are induced Treg (iTreg). iTreg develop from naïve T cells in the periphery and their induction occurs upon T cell receptor stimulation, CD28 co-stimulatory signaling, and in the presence of IL-2 and TGF-β. Phenotypically iTreg resemble nTreg, yet, both populations can be distinguished by the methylation status of a special locus within the Foxp3 gene ([@B8]; [@B100]). In nTreg this locus, the Treg-specific-demethylated-region (TSDR), is fully demethylated allowing for easy transcription while the TSDR in iTreg is methylated. Further discrimination between nTreg and iTreg may be provided by Helios, an Icaros family transcription factor. It has been reported that nTreg express Helios while iTreg do not ([@B96]). Opinion on this topic is divided, some groups claim that Helios only presents an additional activation marker and is mutually expressed by natural Treg and induced Treg ([@B2]; [@B42]).

Apart from these two Treg subsets, non-FOXP3 expressing CD4^+^ Treg have been described such as the IL-10 expressing T regulatory (Tr) 1 cells and TGF-β expressing Th3 cells ([@B99]; [@B80]). Other T cells with regulatory functions have been studied, but less extensively ([@B45]; [@B79]; [@B34]; [@B68]).

These new findings have to be considered when previous Treg work is evaluated. Further research will be required to investigate and to distinguish the influence of MSC on Treg expansion and Treg induction.

THE IMPORTANCE OF TREG INDUCTION BY MSC
=======================================

The fate of MSC in the body after administration has been revealed by multiple distribution studies ([@B7]; [@B59]; [@B32]; [@B4]; [@B102]). Using various types of tracking techniques it was determined that MSC accumulate in the lung after intravenous infusion. The size of cultured MSC is significantly larger than the size of other immune cells in the circulation. This might cause MSC to be trapped in the capillaries of the lung. When MSC were administered via alternative routes, they were also found in other organs such as liver and spleen ([@B88]). Despite the consistency of the data, the drawback of these studies is that researchers cannot be certain that label detection confirms the presence of living MSC. Retrieved label can originate from viable MSC, deceased MSC or possibly phagocytosed debris of MSC.

To gain more clarity on this issue, different approaches have been examined ([@B50]). After intravenous administration of labeled MSC to mice, organs were harvested, and MSC were isolated and re-cultured. Interestingly, labeled MSC were found in the lung up to 24 h after infusion, but in none of the other observed organs at any time after administration.

The apparent shortevity of MSC after infusion fortifies the importance of rapid Treg induction by MSC. While MSC are retained in different tissues shortly after administration and subsequently cleared, they "transfer" their immunomodulatory effect to other immunosuppressive mediators. Hence, when infused MSC are not present any longer to execute their suppressive functions, increased numbers of Treg are available to enforce graft acceptance.

CONCLUSION
==========

Although currently prescribed drug-based immunosuppressive regimen are effective in preventing graft rejection in transplant patients, their main shortcoming is that their long-term application causes malignancies, infections, and nephrotoxicity. Due to their immunomodulatory capabilities, MSC have a high potential to function as alternative immunosuppressive therapy possibly with less side effects. While drugs mainly target a specific molecular pathway to achieve immunomodulation, MSC appear to have a broader effect on the patient's immune system. Yet, further characterization of this more global intervention by MSC is required. Despite inflicting their immunosuppressive effect on most lymphocyte subsets including T cells, MSC spare Treg. In fact, preclinical and clinical studies indicate that MSC mediate the expansion of natural Treg and/or the induction of novel Treg. This becomes an important feature of MSC immunomodulation as MSC appear to be cleared by the recipient's immune system shortly after infusion and hence will not be able to perform their suppressive capacities via direct cell--cell contact or soluble factors. Because of the multifaceted mechanisms by which MSC apply their immunosuppressivity combined with the fact that they do not impair the functionality of host Treg, MSC are very interesting candidates for cellular therapy in transplantation. First clinical results in the field of transplantation should encourage investigators to continue their research to bring MSC therapy to the patient.
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